Anupam Rasayan India Limited (ANURAS) — Financial Results | 30 May 2026
Anupam Rasayan India reported record revenue of ₹2,384 crores in FY26, driven by growth in high-performance materials and pharma segments, with EBITDA at ₹543 crores and net profit of ₹222 crores. The company finalized a definitive agreement to acquire a 43.3%-48.2% stake in Bliss GVS Pharma, targeting a 20-30% CAGR over the next 3-5 years and a pro forma revenue of ₹4,000 crores. Integration plans emphasize synergy realization over 6-18 months, particularly in expanding CDMO capabilities in the U.S., Europe, and India, while maintaining independent operations post-acquisition.
About Anupam Rasayan India Limited (ANURAS)
Chemicals · Chemicals & Petrochemicals · Listed on NSE
📡 Get AI alerts when ANURAS files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track ANURAS — Free💡 Ask AI about this filing
📊 More ANURAS filings
- 🔴 Offer Document — 21 July 2026 Anupam Rasayan India Limited (ANURAS) announced that it, along with its wholly owned subsidiary Mate...
- Announcement — 17 July 2026 Anupam Rasayan India Limited announced it has completed the acquisition of 100% of Mates Visa Consul...
- Announcement — 15 July 2026 Anupam Rasayan India Limited announced it signed a non-binding Letter of Intent with BASQUEVOLT, S.A...
- Financial Results — 25 June 2026 Anupam Rasayan India Limited announced that its trading window will close from July 1, 2026 until 48...
- Announcement — 11 June 2026 Anupam Rasayan India Limited announced on June 11, 2026 that it has become the first company globall...
🔥 Also filed on 30 May 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when ANURAS files new disclosures
Track ANURAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ANURAS — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research